# Microdosed Atropine 0.1% and 0.01% Ophthalmic Solutions for Reduction of Pediatric Myopia Progression

> **NCT03942419** · PHASE3 · TERMINATED · sponsor: **Eyenovia Inc.** · enrollment: 438 (actual)

## Conditions studied

- Myopia

## Interventions

- **DRUG:** Atropine 0.1% Ophthalmic Solution
- **DRUG:** Atropine 0.01% Ophthalmic Solution
- **DRUG:** Placebo Ophthalmic Solution

## Key facts

- **NCT ID:** NCT03942419
- **Lead sponsor:** Eyenovia Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2019-06-03
- **Primary completion:** 2024-10-31
- **Final completion:** 2024-11-20
- **Target enrollment:** 438 (ACTUAL)
- **Why stopped:** Interim Analysis reviewed by Data Monitoring Committee indicated futility
- **Last updated:** 2025-01-06


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03942419

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03942419, "Microdosed Atropine 0.1% and 0.01% Ophthalmic Solutions for Reduction of Pediatric Myopia Progression". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT03942419. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*